{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-024376","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2021-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.137804+00:00","generated_at":"2026-06-28T23:42:19.530863+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Protagenic Therapeutics stockholders approve classified board structure; directors re-elected","bullets":["At Sep 29 annual meeting, all six director nominees elected with votes ranging from 8.37M to 8.88M for each.","Stockholders approved classified board amendment (8.82M for, 150.9K against); filed with Delaware on Oct 1, 2021.","Board classified into three classes: Class I (Buell, Stein) term expiring 2022, Class II (Barrage, Silverman) 2023, Class III (Armen, Corvese) 2024.","MaloneBailey LLP ratified as independent auditor for FY2021 (10.60M for, 2.8K against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-024376","json":"https://secwatch.observer/filing/0001493152-21-024376.json","markdown":"https://secwatch.observer/filing/0001493152-21-024376.md","text":"https://secwatch.observer/filing/0001493152-21-024376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000149315221024376/0001493152-21-024376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000149315221024376/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T23:42:19.530863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}